{
  "guideline": {
    "id": "PA166219103",
    "name": "Annotation of CPIC Guideline for lansoprazole, omeprazole, pantoprazole and CYP2C19",
    "source": "CPIC",
    "version": 6,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166219103",
    "relatedChemicals": [
      {
        "id": "PA450180",
        "name": "lansoprazole",
        "symbol": null
      },
      {
        "id": "PA450704",
        "name": "omeprazole",
        "symbol": null
      },
      {
        "id": "PA450774",
        "name": "pantoprazole",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA124",
        "name": "cytochrome P450 family 2 subfamily C member 19",
        "symbol": "CYP2C19"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166298272",
      "name": "Recommendation PA166298272",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450704",
          "name": "omeprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060874,
        "html": "<p>Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.\nMonitor for efficacy.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal PPI metabolism; may be at increased risk of therapeutic failure compared to CYP2C19 IMs and PMs"
      ],
      "lookupKey": {
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298285",
      "name": "Recommendation PA166298285",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA450774",
          "name": "pantoprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060887,
        "html": "<p>Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.</p>\n"
      },
      "implications": [
        "CYP2C19: Decreased plasma concentrations of PPIs compared to CYP2C19 NMs; increased risk of therapeutic failure"
      ],
      "lookupKey": {
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298290",
      "name": "Recommendation PA166298290",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450774",
          "name": "pantoprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060892,
        "html": "<p>Initiate standard starting daily dose. For chronic therapy (&gt;12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased plasma concentration of PPI compared to CYP2C19 NMs; increased chance of efficacy and potentially toxicity"
      ],
      "lookupKey": {
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298281",
      "name": "Recommendation PA166298281",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA450180",
          "name": "lansoprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060883,
        "html": "<p>Initiate standard starting daily dose. For chronic therapy (&gt;12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased plasma concentration of PPI compared to CYP2C19 NMs; increased chance of efficacy and potentially toxicity"
      ],
      "lookupKey": {
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298263",
      "name": "Recommendation PA166298263",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA450704",
          "name": "omeprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060865,
        "html": "<p>Initiate standard starting daily dose. For chronic therapy (&gt;12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The strength of recommendation for &quot;likely&quot; phenotypes are the same as their respective confirmed phenotypes. &quot;Likely&quot; indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding &quot;likely&quot; phenotype.</p>\n"
      },
      "implications": [
        "CYP2C19: Likely increased plasma concentration of PPI compared to CYP2C19 NMs; likely increased chance of efficacy and potentially toxicity"
      ],
      "lookupKey": {
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298276",
      "name": "Recommendation PA166298276",
      "population": "general",
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA450704",
          "name": "omeprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060878,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2C19: n/a"
      ],
      "lookupKey": {
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298289",
      "name": "Recommendation PA166298289",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450774",
          "name": "pantoprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060891,
        "html": "<p>Initiate standard starting daily dose. For chronic therapy (&gt;12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The strength of recommendation for &quot;likely&quot; phenotypes are the same as their respective confirmed phenotypes. &quot;Likely&quot; indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding &quot;likely&quot; phenotype.</p>\n"
      },
      "implications": [
        "CYP2C19: Likely increased plasma concentration of PPI compared to CYP2C19 NMs; likely increased chance of efficacy and potentially toxicity"
      ],
      "lookupKey": {
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298282",
      "name": "Recommendation PA166298282",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450180",
          "name": "lansoprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060884,
        "html": "<p>Initiate standard starting daily dose. For chronic therapy (&gt;12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The strength of recommendation for &quot;likely&quot; phenotypes are the same as their respective confirmed phenotypes. &quot;Likely&quot; indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding &quot;likely&quot; phenotype.</p>\n"
      },
      "implications": [
        "CYP2C19: Likely increased plasma concentration of PPI compared to CYP2C19 NMs; likely increased chance of efficacy and potentially toxicity"
      ],
      "lookupKey": {
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298273",
      "name": "Recommendation PA166298273",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA450704",
          "name": "omeprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060875,
        "html": "<p>Initiate standard starting daily dose. For chronic therapy (&gt;12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased plasma concentration of PPI compared to CYP2C19 NMs; increased chance of efficacy and potentially toxicity"
      ],
      "lookupKey": {
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298291",
      "name": "Recommendation PA166298291",
      "population": "general",
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA450774",
          "name": "pantoprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060893,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2C19: n/a"
      ],
      "lookupKey": {
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298286",
      "name": "Recommendation PA166298286",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450774",
          "name": "pantoprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060888,
        "html": "<p>Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.\nMonitor for efficacy.</p>\n"
      },
      "implications": [
        "CYP2C19: Decreased plasma concentrations of PPIs compared to CYP2C19 NMs; increased risk of therapeutic failure"
      ],
      "lookupKey": {
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298277",
      "name": "Recommendation PA166298277",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA450180",
          "name": "lansoprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060879,
        "html": "<p>Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.</p>\n"
      },
      "implications": [
        "CYP2C19: Decreased plasma concentrations of PPIs compared to CYP2C19 NMs; increased risk of therapeutic failure"
      ],
      "lookupKey": {
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298270",
      "name": "Recommendation PA166298270",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA450704",
          "name": "omeprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060872,
        "html": "<p>Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.</p>\n"
      },
      "implications": [
        "CYP2C19: Decreased plasma concentrations of PPIs compared to CYP2C19 NMs; increased risk of therapeutic failure"
      ],
      "lookupKey": {
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298283",
      "name": "Recommendation PA166298283",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450180",
          "name": "lansoprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060885,
        "html": "<p>Initiate standard starting daily dose. For chronic therapy (&gt;12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased plasma concentration of PPI compared to CYP2C19 NMs; increased chance of efficacy and potentially toxicity"
      ],
      "lookupKey": {
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298278",
      "name": "Recommendation PA166298278",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450180",
          "name": "lansoprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060880,
        "html": "<p>Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.\nMonitor for efficacy.</p>\n"
      },
      "implications": [
        "CYP2C19: Decreased plasma concentrations of PPIs compared to CYP2C19 NMs; increased risk of therapeutic failure"
      ],
      "lookupKey": {
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298274",
      "name": "Recommendation PA166298274",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450704",
          "name": "omeprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060876,
        "html": "<p>Initiate standard starting daily dose. For chronic therapy (&gt;12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The strength of recommendation for &quot;likely&quot; phenotypes are the same as their respective confirmed phenotypes. &quot;Likely&quot; indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding &quot;likely&quot; phenotype.</p>\n"
      },
      "implications": [
        "CYP2C19: Likely increased plasma concentration of PPI compared to CYP2C19 NMs; likely increased chance of efficacy and potentially toxicity"
      ],
      "lookupKey": {
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298287",
      "name": "Recommendation PA166298287",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450774",
          "name": "pantoprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060889,
        "html": "<p>Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.\nMonitor for efficacy.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal PPI metabolism; may be at increased risk of therapeutic failure compared to CYP2C19 IMs and PMs"
      ],
      "lookupKey": {
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298271",
      "name": "Recommendation PA166298271",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450704",
          "name": "omeprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060873,
        "html": "<p>Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.\nMonitor for efficacy.</p>\n"
      },
      "implications": [
        "CYP2C19: Decreased plasma concentrations of PPIs compared to CYP2C19 NMs; increased risk of therapeutic failure"
      ],
      "lookupKey": {
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297992",
      "name": "Recommendation PA166297992",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA450774",
          "name": "pantoprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060594,
        "html": "<p>Initiate standard starting daily dose. For chronic therapy (&gt;12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased plasma concentration of PPI compared to CYP2C19 NMs; increased chance of efficacy and potentially toxicity"
      ],
      "lookupKey": {
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298284",
      "name": "Recommendation PA166298284",
      "population": "general",
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA450180",
          "name": "lansoprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060886,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2C19: n/a"
      ],
      "lookupKey": {
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298280",
      "name": "Recommendation PA166298280",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA450180",
          "name": "lansoprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060882,
        "html": "<p>Initiate standard starting daily dose. For chronic therapy (&gt;12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The strength of recommendation for &quot;likely&quot; phenotypes are the same as their respective confirmed phenotypes. &quot;Likely&quot; indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding &quot;likely&quot; phenotype.</p>\n"
      },
      "implications": [
        "CYP2C19: Likely increased plasma concentration of PPI compared to CYP2C19 NMs; likely increased chance of efficacy and potentially toxicity"
      ],
      "lookupKey": {
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298279",
      "name": "Recommendation PA166298279",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450180",
          "name": "lansoprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060881,
        "html": "<p>Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.\nMonitor for efficacy.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal PPI metabolism; may be at increased risk of therapeutic failure compared to CYP2C19 IMs and PMs"
      ],
      "lookupKey": {
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298275",
      "name": "Recommendation PA166298275",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450704",
          "name": "omeprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060877,
        "html": "<p>Initiate standard starting daily dose. For chronic therapy (&gt;12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased plasma concentration of PPI compared to CYP2C19 NMs; increased chance of efficacy and potentially toxicity"
      ],
      "lookupKey": {
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298288",
      "name": "Recommendation PA166298288",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA450774",
          "name": "pantoprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060890,
        "html": "<p>Initiate standard starting daily dose. For chronic therapy (&gt;12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The strength of recommendation for &quot;likely&quot; phenotypes are the same as their respective confirmed phenotypes. &quot;Likely&quot; indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding &quot;likely&quot; phenotype.</p>\n"
      },
      "implications": [
        "CYP2C19: Likely increased plasma concentration of PPI compared to CYP2C19 NMs; likely increased chance of efficacy and potentially toxicity"
      ],
      "lookupKey": {
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": "32770672",
      "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.",
      "authors": [
        "Lima John J",
        "Thomas Cameron D",
        "Barbarino Julia",
        "Desta Zeruesenay",
        "Van Driest Sara L",
        "El Rouby Nihal",
        "Johnson Julie A",
        "Cavallari Larisa H",
        "Shakhnovich Valentina",
        "Thacker David L",
        "Scott Stuart A",
        "Schwab Matthias",
        "Uppugunduri Chakradhara Rao S",
        "Formea Christine M",
        "Franciosi James P",
        "Sangkuhl Katrin",
        "Gaedigk Andrea",
        "Klein Teri E",
        "Gammal Roseann S",
        "Furuta Takahisa"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2021
    }
  ],
  "version": "2023-12-19-10-38"
}